Bortezomib (VELCADE®) plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma:: Preliminary results of an IFM phase II study.

被引：19

作者：

Harousseau, JL

Attal, M

Leleu, X

Gressin, R

Hulin, C

Fuzibet, JG

Troncy, J

机构：

[1] CHU Nantes, Dept Hematol, F-44035 Nantes 01, France

[2] Hosp Purpan, Dept Hematol, Toulouse, France

[3] Hosp Claude Huriez, Dept Hematol, Lille, France

[4] Hosp Michallon, Dept Hematol, Grenoble, France

[5] Hosp Brabois, Dept Hematol, Vandoeuvre Les Nancy, France

[6] Hosp Archet, Dept Internal Med, Nice, France

[7] Hosp Edouard Herriot, Dept Hematol, Lyon, France

来源：

关键词：

D O I：

10.1182/blood.V104.11.1490.1490

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1490

引用

页码：416A / 416A

页数：1